Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
about
Acquired myelodysplasia or myelodysplastic syndrome: clearing the fogCytokine network involvement in subjects exposed to benzene.The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromesTh22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromesCD4+CD25highFoxP3+ regulatory T-cells in hematologic diseasesBMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progressionInflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases.Myelodysplastic syndromes and autoimmune diseases--case series and review of literatureImmunological derangement in hypocellular myelodysplastic syndromes.Emerging immunosuppressive drugs in myelodysplastic syndromes.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Peptide vaccines for hematological malignancies: a missed promise?Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum.Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Immune checkpoint pathways: perspectives on myeloid malignancies.Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome.The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.Acute myeloid leukemia following exposure to benzene more closely resembles de novo than therapy related-disease.Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes.KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes.Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report.
P2860
Q28662217-EA41B48A-EE4C-49F2-ADE6-A61586A803DBQ34118812-711C4FCC-2FD6-4CA8-B904-EC84DECDDCC7Q34429788-D0AF170B-2412-4C89-B164-E5DC425DCE91Q34510880-9B5F5DB5-F3F3-478E-A3F0-ADE0F0712B38Q34613086-B8891582-A517-4FCD-8C64-BBFD7EB2CCC2Q35300172-3148E26C-E666-4FC7-8665-40C61040DB5AQ35867819-73E9FF13-A9FA-4BA9-99A7-1130078F0B28Q36193594-F877BFCE-5ED1-4684-96EB-DC934BA4CFFAQ36976674-0A35416D-37F2-422F-AE24-39C44B47A0BBQ37724605-7E4F421A-F666-4B88-BBF9-AFC1D612EA1EQ38060835-52C368DF-2602-4435-848B-F5322E996F21Q38110935-15D69B43-CB31-4107-9D11-628618026F60Q38176546-751A8EB6-DB75-48E8-9C51-03A004C6709AQ38194601-AF4F9EFC-9EA3-4438-A290-045B74D8F421Q38196461-8B8627B1-4938-48E7-A300-A345FECFBA80Q38283075-3C4FFECE-40BD-4DBE-8CFA-2862CB76DAF4Q38415206-3F79F376-0D0B-4ABB-B660-988A0570CE67Q38750608-9219C405-3007-49BF-BC05-97F38C60CEF7Q38826127-B071C3EF-D0C9-4A6F-AD31-56F1A3A884ADQ38921459-28BCBDE3-4141-4619-B9B2-384984FD891BQ39072004-29B4D7C3-352B-4C37-8A5E-363051E3D340Q39279547-23E4C7A4-832A-4A4E-913F-BD1619985D11Q40390447-31F58D6D-FE17-4BC1-A3F2-E14D12E94EB2Q40592382-806C6E3E-5D0F-4299-BC98-933F7CA847ECQ42036124-B8A2A01F-06E4-4061-9DB5-D98237B9618DQ44128833-6FDD4338-67AE-4F1B-99F7-918C1A6A83F8Q45079106-31D7431B-32D7-4BD3-BD91-6782476A5F22Q46105174-BAC4B863-44E6-49ED-BECA-BDBF8D00D597Q47116205-52EE468F-E46A-4D42-BA7A-CCFF413933A5Q47123872-F0DECDA2-2011-4964-A1D5-1B5F7A0E9C5AQ48252834-B10974EB-FE88-4D41-9AFD-C681C201325AQ49021366-7C209C85-9647-41C9-AB8B-7AF95CB4836FQ54348216-3FE4EDB9-618D-4E14-A4E4-F69DF8C7B46CQ55257366-DCB28B67-7BBE-490C-829F-995434ADD4EA
P2860
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of immune responses in th ...... mplications for immunotherapy.
@en
Role of immune responses in th ...... mplications for immunotherapy.
@nl
type
label
Role of immune responses in th ...... mplications for immunotherapy.
@en
Role of immune responses in th ...... mplications for immunotherapy.
@nl
prefLabel
Role of immune responses in th ...... mplications for immunotherapy.
@en
Role of immune responses in th ...... mplications for immunotherapy.
@nl
P2093
P2860
P1476
Role of immune responses in th ...... mplications for immunotherapy.
@en
P2093
Arjan A van de Loosdrecht
Canan Alhan
Gert J Ossenkoppele
Hetty J Bontkes
Shikhar Aggarwal
Theresia M Westers
P2860
P304
P356
10.1111/J.1365-2141.2011.08683.X
P407
P577
2011-04-13T00:00:00Z